Literature DB >> 12970748

Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.

Gerald E Stoica1, Thomas F Franke, Maria Moroni, Susette Mueller, Elisha Morgan, Mary C Iann, Abigail D Winder, Ronald Reiter, Anton Wellstein, Mary Beth Martin, Adriana Stoica.   

Abstract

Epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), and heregulin-beta1 (HRG-beta1), can modulate the expression and activity of the estrogen receptor-alpha (ER-alpha) via the phosphatidylinositol 3-kinase (PI 3-K)/Akt pathway in the ER-alpha-positive breast cancer cell line, MCF-7. Estradiol can also rapidly activate PI 3-K/Akt in these cells (nongenomic effect). The recent study examines whether Akt is involved in the ER-alpha regulation by estradiol (genomic effect). Stable transfection of parental MCF-7 cells with a dominant-negative Akt mutant, as well as the PI 3-K inhibitors wortmannin and LY 294,002, blocked the effect of estradiol on ER-alpha expression and activity by 70-80 and 55-63%, respectively. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of estradiol. The changes in ER-alpha expression and activity were abrogated in response to estradiol by an arginine to cysteine mutation in the pleckstrin homology (PH) domain of Akt (R25C), suggesting the involvement of this amino acid in the interaction between Akt and ER-alpha. Experiments employing selective ErbB inhibitors demonstrate that the effect of estradiol on ER-alpha expression and activity is mediated by ErbB2 and not by EGFR. Moreover, anchorage-dependent and -independent growth assays, cell cycle and membrane ruffling analyses showed that Akt exerts estrogen-like activity on cell growth and membrane ruffling and that a selective ErbB2 inhibitor, but not anti-ErbB2 antibodies directed to the extracellular domain, can block these effects. In the presence of constitutively active Akt, tamoxifen only partially inhibits cell growth. In contrast, in cells stably transfected with either a dominant-negative Akt or with R25C-Akt, as well as in parental cells in the presence of a selective ErbB2 inhibitor, the effect of estradiol on anchorage-dependent and -independent cell growth was inhibited by 50-75 and 100%, respectively. Dominant-negative Akt inhibited membrane ruffling by 54%; however, R25C-Akt did not have any effect, suggesting that kinase activity plays an important role in this process. Scatchard analysis demonstrated a 67% reduction in estrogen-binding capacity in cells transfected with constitutively active Akt. No change in binding affinity of estradiol to the receptor was observed upon transfection with either Akt mutant. Taken together, our results suggest that estradiol treatment results in binding to membrane ER-alpha and interaction with a heterodimer containing ErbB2, leading to tyrosine phosphorylation. This results in the activation of PI 3-K and Akt. Akt, in turn, may interact with nuclear ER-alpha, altering its expression and activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970748     DOI: 10.1038/sj.onc.1206769

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

Review 1.  Disruption of androgen receptor signaling in males by environmental chemicals.

Authors:  Doug C Luccio-Camelo; Gail S Prins
Journal:  J Steroid Biochem Mol Biol       Date:  2011-04-13       Impact factor: 4.292

Review 2.  Integration of the extranuclear and nuclear actions of estrogen.

Authors:  Ellis R Levin
Journal:  Mol Endocrinol       Date:  2005-02-10

3.  Estrogen increases secretion of stromal cell derived factor-1 in human breast cancer cells.

Authors:  Fengliang Zhang; Hua Kang; Qing Xu
Journal:  Int J Clin Exp Med       Date:  2014-11-25

4.  Distinct transcriptional regulation of human large conductance voltage- and calcium-activated K+ channel gene (hSlo1) by activated estrogen receptor alpha and c-Src tyrosine kinase.

Authors:  Shahab M Danesh; Pallob Kundu; Rong Lu; Enrico Stefani; Ligia Toro
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

5.  Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.

Authors:  Mohammed S Orloff; Xin He; Charissa Peterson; Fusong Chen; Jin-Lian Chen; Jessica L Mester; Charis Eng
Journal:  Am J Hum Genet       Date:  2012-12-13       Impact factor: 11.025

6.  Interaction of the double-strand break repair kinase DNA-PK and estrogen receptor-alpha.

Authors:  Senad Medunjanin; Sönke Weinert; Alexander Schmeisser; Doris Mayer; Ruediger C Braun-Dullaeus
Journal:  Mol Biol Cell       Date:  2010-03-10       Impact factor: 4.138

7.  Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.

Authors:  Carmen Blanco-Aparicio; Marta Cañamero; Yolanda Cecilia; Belén Pequeño; Oliver Renner; Irene Ferrer; Amancio Carnero
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

8.  Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.

Authors:  Catia Morelli; Marilena Lanzino; Cecilia Garofalo; Pamela Maris; Elvira Brunelli; Ivan Casaburi; Stefania Catalano; Rosalinda Bruno; Diego Sisci; Sebastiano Andò
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

9.  A sex- and region-specific role of Akt1 in the modulation of methamphetamine-induced hyperlocomotion and striatal neuronal activity: implications in schizophrenia and methamphetamine-induced psychosis.

Authors:  Yi-Wen Chen; Hui-Yun Kao; Ming-Yuan Min; Wen-Sung Lai
Journal:  Schizophr Bull       Date:  2013-03-08       Impact factor: 9.306

10.  Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor.

Authors:  Miltiadis Paliouras; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2008-01-09       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.